HYPERKALEMIA AFTER HOSPITALIZATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: FINDINGS FROM THE ASTRONAUT TRIAL
2018
Hyperkalemia (hyperK+) may limit the optimal use of RAAS inhibitors and represents an emerging target for therapy. We report rates, temporal patterns, and key predictors of hyperK+ after hospitalization for HFrEF.
The ASTRONAUT trial randomized 1,639 HFrEF patients with EF≤ 40% and elevated NP
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI